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The Role of the University in Promoting Human
Embryonic Stem Cell Research and Stem Cell
Therapies
Dan S. Kaufman, MD, PhD, Associate Professor, Stem Cell
Institute and Department of Medicine, Division of
Hematology, Oncology, and Transplantation, Translational
Research Facility, University of Minnesota
When asked about what the University should do to
support or promote stem cell research, my view as a physicianscientist is that the University should allow and promote
innovation. Specifically, innovation in a direction that will help
us learn new knowledge about diseases and possible treatments
to develop novel therapies that will push the envelope and help
better treat and potentially cure those conditions that are
currently incurable. As a faculty member in the Stem Cell
Institute and the Department of Medicine at the University of
Minnesota, my area of research interest is to use stem cells to
understand blood cell development. There are many different
views on the question of how we push this field of stem cell
research in general, and nuclear transfer in particular, toward
novel clinical therapies. In my academic life, I routinely go back
and forth between the clinic and the lab. This allows clear
understanding of the needs and challenges in the areas of basic
and clinical research, and how to potentially bring these areas
together.
As an example of the potential for successful stem cell
therapies, it is informative to recall the scientific and
technological innovation that developed in the field of
hematology and bone marrow transplant (“BMT”). The first
successful BMT anywhere in the world was performed at the
University of Minnesota in 1968. 1 This was not the first BMT
attempted, but was the first that succeeded. The patient was an
1. Richard A. Gatti et al., Immunological Reconstitution of Sex-Linked
Lymphopenic Immunological Deficiency, 292 LANCET 1366, 1366–69 (1968).
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infant with an immunodeficency that would typically be lethal
because his body could not effectively fight common infections.
He received bone marrow cells from his sister, and those cells
engrafted his bone marrow and made all the blood cells he
needs for an entire lifetime, including lymphocytes needed to
fight infections. It is important to recognize that bone marrow
transplantation is stem cell therapy. We can take bone marrow
that contains blood stem cells from one person, typically a
brother or sister, and transplant those to a patient with life
threatening diseases, typically blood cell cancers or
immunodeficiencies. 2 Under the proper conditions those blood
stem cells will live in the body of the recipient for the rest of
his/her life.
Thirty-eight years have passed since that first successful
BMT, making that the longest period of time that we know a
stem cell therapy will work.
However, even despite
considerable progress over four decades, these transplants still
have a high rate of problems that cause severe, potentially
lethal side effects in the recipient. 3 It still seems that the
successful cases occur when the stars are aligned properly: you
need the right donor and a recipient who is suffering from a
life-threatening disease but not so sick that the treatment
being done to save a life would unfortunately kill a patient
instead. We have learned about the types of cancers where
stem cell therapy (in the form of BMT) is effective. However,
20% or more of recipients of allogeneic transplants (from one
person to another) will still die in the first year from the
treatment alone. 4 Therefore, because of the dangers involved in
the procedures, we are still not going to do an allogeneic
transplant in many cases. Despite thirty-eight years of
research on this, this is how far we have advanced. It is great
for the patients when these transplants work—we can actually
cure those diseases that would be otherwise be incurable.
However, with the continued high rate of morbidity and
mortality we are only going to do it on the most severe cases.
For less severe diseases (i.e., autoimmune diseases), the benefit
2. Edward A. Copelan, Hematopoietic Stem-Cell Transplantation, 54
NEW ENG. J. MED. 1813, 1813 (2006).
3. Id.; see also E. Donnall Thomas & Karl G. Blume, Historical Markers
in the Development of Allogeneic Hematopoietic Cell Transplantation, 5
BIOLOGY BLOOD & MARROW TRANSPLANTATION 341 (1999).
4. Copelan, supra note 2, at 1822.
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may not be worth the risk.
In my perspective, we now have an established experience
and body of knowledge regarding stem cell-based treatments in
the form of BMT. We have room to make more real paradigmshifting treatment changes in the field of cancer therapy.
Currently, if you have diseases such as lung cancer or multiple
myeloma or kidney cancer, it is great for drug companies and
those performing the clinical trials if the pharmaceutical
companies develop a new drug that improves your life span by
six months. From my vantage point, however, this incremental
advance is less then optimal. We want treatments that will not
just treat but cure the underlying diseases. That is exactly
what stem cell therapies have to offer. There is considerable
interest at the University of Minnesota to facilitate stem cell
research using everything at our disposal to push this field
forward in the most innovative and most productive way
possible. These directions include adult stem cells, embryonic
stem cells, and potentially nuclear transfer. This is an
important and rapidly developing area.
The Stem Cell
Institute at the University of Minnesota (and at other
institutions) helps promote advances to this field, but clearly
we have a long way to go before we can successfully cure a wide
range of devastating diseases. The next ten years will be really
exciting. New treatments and cures will come from these
endeavors and support of stem cell research. However, it is also
essential to communicate that many of these new treatments
may not be directly cell-based therapies. Instead, these
treatments will come about from these new cell-based assays
and tools developed from the basic research. In my view this is
really where things are, and hopefully where the field is going.
While I do not have formal training in bioethics, I certainly
have a first hand perspective of the issues that are considered
by patients, physicians, and researchers and have considered
ethical and public policy issues related to human embryonic
stem cell and nuclear transfer research. Clearly there are
differences of opinion regarding ethical perspectives on this
type of research. However, my view as a physician who cares
for patients who die of cancer becomes quite clear, and I think
typical for many working closely in this field, especially with
patients who may one day benefit from advances in stem cell
research. I feel that it is actually morally imperative that stem
cell research, that can and will impact so many diseases, be
moved forward in as expeditious a manner as possible. The list
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of diseases that are often touted in terms of potential stem cellbased therapies include spinal cord injury, diabetes,
Parkinson’s disease, cancer, and others. All of these diseases
often have no good treatments and cause significant suffering
and deaths of millions of patients every year. Therefore, I
think reinforcing what the role of the University in this process
would be to facilitate working with policy makers, as well as
have appropriate oversight by ethical and clinical trial review
committees, so that these basic research studies and eventual
clinical trials can be done in as open and productive a manner
as possible. This is an exciting area of research that implicates
science, ethics, and public policy in a field that truly represents
twenty-first century medicine.

